Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs Concomitant Ceftazidime-avibactam + Aztreonam for MBL-CR-GNB Infections
NCT07478484Phase 4Recruiting
- Sponsor
- Jing Medicine
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Irreversible Covalent Inhibitors, Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, randomised trial of ceftazidime + avibactam and aztreonam in Gram-negative bacterial infection (2 arms), sponsored by Jing Medicine. Primary endpoint: Clinical cure rate at 14 days. Started Mar 2026; status: recruiting.
02
Drugs
ceftazidime + avibactamaztreonam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT07478484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478484.